The purpose of this study is to determine whether accelerated BEP chemotherapy is more
effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic
germ cell tumours.
Bleomycin, Etoposide, Cisplatin (BEP) administered 3-weekly x 4 remains standard 1st line
chemotherapy for intermediate- and poor-risk metastatic germ cell tumours (GCTs). Cure rates
are over 90% for good-risk disease, 85% with intermediate-risk, and about 70% for poor-risk
disease. Previous strategies to improve first-line chemotherapy have failed to improve cure
rates and were more toxic than BEP. New strategies are needed for patients with intermediate
and poor-risk disease. BEP is accelerated by cycling Cisplatin and etoposide 2-weekly instead
of 3-weekly. The Australian and New Zealand Urogenital and Prostate Cancer Trials Group
(ANZUP) is conducting a trial comparing accelerated BEP with standard BEP. The aim of this
study is to determine if accelerated BEP is superior to standard BEP as first-line
chemotherapy for intermediate and poor risk metastatic GCTs.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.